ChroMedX Corp Announces Grant of Options

Toronto, Ontario
October 6, 2014

ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (the "Company") announces that it has granted an aggregate of 600,000 options to purchase common shares of the Company exercisable at a price of $0.18 per share and expiring on October 6, 2017, to certain consultants of the Company. The consultants concerned bring expertise to the Company in several key areas. These include the electrochemical and spectroscopic technologies incorporated in the Company's HemoPalm blood analysis system, as well as industry expertise in both the North American and European markets. The common shares issuable upon exercise of the options are subject to a four-month hold period from the original date of grant.

Recent Activities

On September 22, 2014 ChroMedX Corp. announced the close of an oversubscribed private placement for gross proceeds of CDN$614,500 to advance the development of its patented HemoPalm handheld device & cartridge technology.

About ChroMedX Corp.

ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.: 
Website: www.chromedx.com 
Facebook: facebook.com/chromedxcorp
Twitter: www.twitter.com/Chromedxcorp

Contact 
Wayne Maddever 
President, CEO & Director 
647-872-9982

W. Clark Kent 
Corporate Development 
647-519-2646 
ckent@chromedx.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available atwww.sedar.com.

The security symbol, MNLIF, is part of the OTC Grey Market, where Monarch does not provide any reports and has no obligation to do so. There are no market makers under this symbol of this security. It is not listed, traded or quoted on any U.S. stock exchange or the OTC Markets. Trades in grey market stocks are reported by broker-dealers to their Self Regulatory Organization (SRO) and the SRO distributes the trade data to market data vendors and financial websites so investors can track price and volume. Since grey market securities are not traded or quoted on an exchange or interdealer quotation system, investor's bids and offers are not collected in a central spot so market transparency is diminished and best execution of orders is difficult.